" /> Alcor News: October 2007 Archives

« September 2007 | Main | November 2007 »

October 19, 2007

2007 Membership Directory

Alcor received an overwhelming response from its members who asked to be included in the 2007 Alcor Membership Directory. Nearly half of Alcor's members requested to be included, although all members will receive a copy of the directory in the next few weeks. Even those who aren't listed are encouraged to use the contacts listed to form local support groups. The purpose of the directory is to bring members together. Those who form a new group that meets regularly are encouraged to contact Alcor for announcement of the group to a wider audience, which spurs new attendees. One caveat - Alcor asks members to respect the privacy of those included in the directory by not taking the directory to public places or sharing it with non-members.

October 18, 2007

Foresight Vision Weekend Open to Alcor Members

Foresight Nanotech Institute's Vision Weekend to be held Nov. 3-4 is open to Alcor members, as well as members of other special cooperating groups. Usually this event is only open to their Senior Associate members.

Alcor encourages you to check out this event and register early. It is an "unconference," so attendees have the option of presenting as well as general participation. The overall theme is advanced technologies, with a wide variety of topics to be covered, including a presentation on cryonics by Alcor's Tanya Jones.

Facebook users can indicate their plans to attend here, though RSVPs here don't guarantee you a seat.

Hope to see you there!

October 15, 2007

Thank You for Making the 7th Alcor Conference a Success!

We hope all our conference attendees enjoyed the 7th Alcor Conference, from the lively discussions to the food selections, sleeping rooms, and beautiful Arizona weather. The event could not have been a success without our attendees, and so we thank them all for supporting our mission!

The 7th Alcor Conference DVD set is still in production, but it can be ordered now for only $39.95 plus shipping - a special sale price only available for a limited time. Order yours now to receive this 20% discount.

Anyone interested in reading more about the conference is encouraged to view these blogs:
Frontier Channel
People Database Project
Fight Aging
TechNewsWorld


We hope to see everyone at the 8th Alcor Conference!

October 11, 2007

CR Society Conference

The fifth CR Society Conference will be held at Sunset Station in San Antonio, TX. The Conference will run from Wednesday November 7 through Sunday November 11, 2007. The Conference will open with a welcoming reception/registration on Wednesday evening November 7 starting at 6:30 pm. The presentations will start Thursday November 8 at 9:00 am and end Sunday Sunday November 11 at 11:00 am.

The Conference webpage:
http://www.calorierestriction.org/conferences-2007
Sunset-Station
http://www.sunset-station.com/home.html

Map of Sunset-Station and our hotels
http://www.sunset-station.com/abouthss/locationmap.html


The current roster of participating scientists includes:

Edward Masoro http://www.kronosinstitute.org/Biographies/biography-masoro.html

Steven Austad http://www.uthscsa.edu/csb/faculty/austad.asp

John Holloszy http://research.medicine.wustl.edu/ocfr/research.nsf/s/6496C5D326194AB48625678D00602049

Jim Nelson; http://www.barshop.uthscsa.edu/Nelson.html

Jay Phelan; http://lifeboat.com/ex/bios.jay.phelan?print

Arlan Richardson; http://www.uthscsa.edu/csb/faculty/richardson.asp

Walter Ward; http://www.uthscsa.edu/faculty/ward.html

Bradley Willcox; http://www.okicent.org/team.html

We also will include presentations by members of the Society.

We will have two banquet style meals. There will be one lunch on Thursday and one dinner on Saturday.
The meals will be a salad bar buffet with a selection of vegetables, fruit, nuts and chicken breast (lunch) or Salmon (dinner). More details about the menu will be available soon.

Lunch $24

Dinner $36

Both Meals $50

We are offering an optional banquet style dinner on Saturday November 10th of
the Conference. Many of you have already signed up when you registered
on-line, but it's still available.

DINNER SELECTION

Buffet Style Salad Bar
To Include:
Spring Mix Lettuce
With the Following Build Your Own Salad Condiments:
Grape Tomatoes
Cucumber Wheels
Broccoli Florets
Cauliflower Florets
Carrots
Celery
Yellow Squash
Green Squash
Red Onion
Mushrooms
Red or Yellow Peppers
Raw and Unsalted
Sunflower Seeds
Walnuts
Pecans

A Selection of zero calorie dressing to Be Provided By Walden Farms
(this will be their fourth Conference Sponsorship by providing a large
selection of their very low calorie dressings, sauces, dips, and jelly for
meals and attendee take home samples)
http://www.waldenfarms.com/
Offered in Chafing Dishes:
Baked Salmon
Lightly Steamed Asparagus

Fresh Fruit Display
Assorted Seasonal Fruit
Cantaloupe
Honeydew Melon
Watermelon
Kiwi
Red Grapes
Strawberries
Blueberries
Raspberries
Blackberries

Iced Tea
Water

We are offering an optional banquet style lunch on Thursday November 8th of
the Conference. Many of you have already signed up when you registered
on-line, but it's still available.

BUFFET LUNCH SELECTIONS

Buffet Style Salad Bar
To Include:
Spring Mix Lettuce
With the Following Build Your Own Salad Condiments:
Grape Tomatoes
Cucumber Wheels
Broccoli Florets
Cauliflower Florets
Carrots
Celery
Yellow Squash
Green Squash
Red Onion
Mushrooms
Red or Yellow Peppers

And
Raw and Unsalted
Sunflower Seeds
Walnuts
Pecans

A Selection of zero calorie dressing to Be Provided By Walden Farms
(this will be their fourth Conference Sponsorship by providing a large
selection of their very low calorie dressings, sauces, dips, and jelly for
meals and attendee take home samples)
http://www.waldenfarms.com/
Offered in Chafing Dishes:
Lean Baked Chicken Breasts

Fresh Fruit Display
Assorted Seasonal Fruit
Cantaloupe
Honeydew Melon
Watermelon
Kiwi
Red Grapes
Strawberries
Blueberries
Raspberries
Blackberries

Iced Tea
Water

October 7, 2007

7th Alcor Conference, Sunday Morning Sessions

Special Guest Writers: John Schloendorn & Simone Syed

Sunday began with a panel discussion about the ethics of life and death, the relationship between cryonics and critical care medicine, and about the definition of death, which has profound implications for cryonics. The panelists were critical care physician David Crippen, Alcor COO Tanya Jones, and bioethicist Leslie Whetstine. Next, Steven Harris, MD introduced his perfluorocarbon-based rapid body cooling system, which has applications in cryonics and emergency medicine. Calvin Mercer, PhD addressed the relationship between religion and life extension practices, such as cryonics. Christine Petersen then provided a survey of existing life extension technologies, and, finally, Chris Heward, PhD wrapped up with an in-depth account of the aging measurement experiment being conducted at Kronos Science Laboratory.

David Crippen, MD, Tanya Jones, Leslie Whetstine, PhD (by Simone Syed)
Cryonics and Critical Care Medicine Panel

One of the main topics covered by this panel was the definition of death, which is currently fragmented. Does death result with failure of the heart or with brain death? The heart can still beat in a brain-dead person, and the brain can still work in a body whose heart has stopped. There needs to be a unified definition of death, instead of the splintered criteria currently utilized.

Death upon cardiac death helps in cryonics cases because cryonics technicians are concerned about the future viability of the brain. Clearly, brain death is not desired. Leslie, however, finds that she cannot rely solely on the cardiac definition of death because the person is certainly still revivable. Therefore, she does not consider them dead until they cannot be revived. Cryonic facilities must establish a rapport with hospitals to ensure that the stabilization process is started as soon as possible after cardiac arrest, instead of waiting around for the brain to die.

To rebut Leslie's statement that the industry may be considered dishonest due to conflict with the legal terminology of death, Tanya Jones stated that cryonics patients are only "mostly dead," therefore she does not believe that she is being dishonest in any form. Leslie also admits that she is very unaware of the implications of cryonics in a legal sense.

There was some discussion of the definition of death that clinicians must adhere to and the criteria that must be met for procurement of organs. Clinicians take the time to go through an entire list of criteria in order to establish, without a doubt in their minds, that the patient is in fact dead. However, it can be difficult to determine whether or not brain death has occurred, especially since there are always emerging standards and methods of determination.

Dr. David Crippen stated that the person does not have to be only legally dead, but rather permanently dead. How do you know if someone is permanently dead, though? Waiting around for so-called permanent death wastes precious time in the process of cryonics, and as pointed out by one adamant questioner during the Q&A session, the point of cryonics is that the people who are being cryopreserved are at least partially viable and living on the cellular level, otherwise there would be no use in applying the cryonics protocol.

Tanya commented that it would be ideal for cryopreservation to become a medical procedure performed in hospitals under circumstances that allow for optimal viability of the brain. Acceptance in the medical community requires people to start a dialogue with their families and their primary care physicians. By familiarizing those around them with the concept of cryonics, it becomes a more visible and credible technology.

*

Steven B. Harris, MD (by John Schloendorn)
Rapid Hypothermia Induction Methods and Brain Oxygen Requirements in Resuscitation and Cryonics

Dr. Steven B. Harris is a medical doctor with board certifications in internal medicine and geriatrics. Steven talked to us about his investigational rapid body cooling procedure. At a temperature drop of more than 1 degree C/min in dogs, this is the fastest known procedure for cooling bodies. The protocol involves injecting a cooled perfluorocarbon-oxygen mix into the patient’s lungs, essentially using the lungs as a heat-exchanger for the body. The lungs are extremely well-suited for this, because their surface area is very large, and all the body's blood circuits flow through it.

The perfluorocarbons then rapidly evaporate, cooling the blood in the process. Steven showed data suggesting that his procedure causes an efficient transfer of heat from the brain and the peripheral organs and touched on the applications of rapid cooling procedures in both resuscitation and cryonics. For instance, cooling can be used to reduce ischemic damage to heart attack victims until they can be transported to a hospital for resuscitation. Even using traditional, slower cooling techniques, mild clinical benefits of cooling in such cases have been demonstrated. For cryonics, rapid cooling is of course desirable in the initial stages because it reduces ischemic damage and other forms of damage to the patient’s brain. Steven took us through various instrumental improvements he has made to the system over the years.

Calvin Mercer, PhD (by John Schloendorn)
Cryonics and Religion: Friends or Foes?

Dr. Mercer started by stating that religions are incredibly powerful constructs in our culture. Therefore, whoever wishes to fare well in this world may consider interacting with people of various religious faiths. According to Calvin, life extensionists, in their perpetual quest for science funding, may desire productive interactions with large numbers of religious people. On the contrary, however, history shows that religion quite often opposes scientific progress or particular scientific procedures.

So, how can productive interactions with religions take place? As a historian of religion, Dr. Mercer notes that all religions have evolved over time and will continue to evolve. Thoughtful, religious people, in turn, should consciously direct this process. This process will be difficult and the outcome somewhat unpredictable due to the complex interactions between individuals belonging to various “camps” in each religious association. Examples include anthropocentric vs. theocentric, this-worldly vs. other-worldly, pragmatic vs. dogmatic, or revisionist vs. traditionalist attitudes. This complexity can frustrate “outsiders” seeking to interact with scholars of any particular religion. Mercer broadly divided these camps into liberal forces (terms preceeding the “vs.” above) and conservative forces (terms following the “vs.” above).

Liberal-leaning individuals are often open to the ideas of science and life extension, but they are often cautious of potential adverse social effects. The conservative camp, on the other hand, is mostly concerned with the possibility of a contradiction between life extension practices and their religious dogma. Violating such dogma may incur divine punishment, and conforming to said dogma may entice divine reward, thus providing a major force-driving decision in the life of a conservative. Based on this fear of punishment, Calvin proposes an intriguing way to show the conservative camp that life extension is compatible with their beliefs: If life extension could be understood as a way to gain more time to figure out how to best conform with God’s Will on this earth, conservatives might appreciate it as a way to reduce their odds of divine punishment and improve their odds of divine reward.

There was some discussion, as earlier in the day, about the definition of death. Like cryonicists, religious people have varying definitions of death. Most of these are spiritually-based, but they may have morally relevant correlations with cryonicists’ scientifically-based definitions. Flexible death definitions, too, could provide some of the mechanics needed to dodge head-on conflicts with conservative dogmas.

Christine Peterson (by Simone Syed)
Life Extension: Good News, Bad News, Surprising News

Christine discussed getting serious about life extension and how it can be a fun thing. We are trying to extend healthy life, not extend an unhealthy period of old age, and the term health extension does not imply increasing total years.

Christine states that it would be nice to be able to take a pill everyday for all the days that you want to live, and when you are finished living, then simply stop taking the pill. Unfortunately, we do not have such a pill now, and we do not have the science to make one either. But she quotes Bill Clinton as saying, “We want to live forever, and we are getting there.”

Various approaches give us many different ways to seek life extension, including living a healthy lifestyle and using nanotechnology to repair bodies on a cellular level and a molecular level. We would like true nanomedicine that is reliable to control processes on the biological level. Christine says that we need to start applying anti-aging methods in order to buy some time before the more complex methods actually become viable and advocates these ways to buy some time right now:

Stress reduction
Physical risk reduction
Mood improvement
Sex: quality for women, quantity for men
Eating healthy
Rest relaxation
Sleep
Vacations
Supplements
Exercise

She also encourages people to get biomarker testing to get a baseline before starting a life extension program.

One aggressive approach to life extension is calorie restriction. This works in rats, but not in fruit flies, for instance. So, it is still unknown whether it will work in humans. However, the tests done on monkeys show that those that are on a restrictive diet look much better than those not on the diet. Regardless, being on a healthy diet is a good idea, and it should be implemented. Exercise is also important. Christine recommends walking about 10,000 steps a day to stay fit.

Commentary:
Christine Peterson takes a lot of time to discuss how she feels about food and eating. It was rather informative, particularly for people who have limited knowledge about life extension practices.

*

Christiopher B Heward (By John Schloendorn)
The Kronos Longitudinal Aging Study: The Measurement of Human Aging

The rationale behind the Kronos program for identifying biomarkers of aging is to measure human aging in as much detail as possible, so that pathology can be predicted before it occurs and the efficacy of anti-aging interventions can be monitored in near real-time. The program measures hundreds of variables throughout the body, including physiological, biochemical and metabolic parameters, which all deteriorate with aging. Each of the markers individually suffers within a huge amount of variance. Kronos seeks to use statistics to put their mutually dependent and independent markers together into one coherent image of the gradual physiological decline we suffer in aging.

It seems apparent that an organism can live only as long as its weakest critical system. Thus, long-lived persons appear to age not necessarily more slowly, but more uniformly in all organs. The Kronos program should become able to identify the fastest-declining system far ahead of time. It could then be pushed onto a slower track with a targeted intervention. This would require undergoing the biomarker testing at a reasonably young age.

Of special interest to cryonicists is Alzheimer’s disease, because it threatens to destroy personality before cryopreservation. Kronos has identified multiple new genetic variations that pre-dispose people to Alzheimer’s disease. This could lay the foundation for personalized preventative Alzheimer’s treatments.

Finally, Dr. Heward touched on the much-debated Women’s Health Initiative, which failed to offer the expected benefits of estrogen replacement in post-menopausal women. Kronos discovered that this study included only very old women, because they wanted to include death as an end-point. Kronos is now enrolling younger women, in whom estrogen levels have only recently declined, because the Kronos biomarker program can act as a substitute for the death end-point in the clinical trials. These younger women are arguably more likely to benefit from hormone replacement, because they will spend less or no time with depressed estrogen levels.

October 6, 2007

7th Alcor Conference, Saturday Afternoon Sessions

Special Guest Writers: John Schloendorn & Simone Syed

The afternoon session featured several illustrious speakers from the fields of nanotechnology and stem cell research, which would seem indispensable for successful revival from cryopreservation. The session began with an introduction to molecular nanotechnology from Ralph Merkle, PhD, which may one day allow us to rebuild damaged structures molecule-by-molecule. Mike West, PhD, of Advanced Cell Technology, discussed how one day we may be able to reassemble lost human tissues and organs cell-by-cell. Finally, Aubrey de Grey, PhD, most well-known for his Strategies for Engineered Negligible Senescence (SENS) (a strategy to cure human aging by repairing the damage it does to the human body), provided an intriguing account of whether it is politically safe for a biologist to support cryonics publicly. Speaking from his own experience, Aubrey’s conclusion is no, it is not safe at all, but hiding it is a lot more dangerous!

Ralph Merkle, PhD (by Simone Syed)
Molecular Nanotechnology and the Repair of Cryopreserved Patients

Dr. Ralph Merkle is a PhD from Stanford University with success in public key cryptography. He was a nanotechnology theorist at Xerox Palo Alto Research Center and Zyvex Corporation.

Ralph believes that the brain structures proposed to contain long-term memory can be preserved by cryonics and that it may be possible to use cryptography to restore the damage done by the cryopreservation process.

When considering "What is nanotechnology?" he jokingly defined it as "Anything that will get me money or a grant!" In all seriousness, nanotechnology will allow us to arrange atoms in most of the ways permitted by physical law. We will be able to get almost every atom in the right place, and manufacturing cost will be low. Such capability will certainly be useful to revive people that have been cryopreserved.

Ralph states that positional assembly is a wild and exciting area that is being explored. The general idea is that creating molecular tools requires positional assembly and would require 6 degrees of freedom with highly reactive compounds and an inert environment. The ultimate goal is to be able to make almost anything of high complexity using all of the elements in the periodic table. The simplest way to go about this is to reduce the number of elements that we use.

An analysis resulted in nine different molecular tools to perform basic operations. These tools are amazingly small and they work with singular atoms (such as a hydrogen donator, a methylene tool that will donate a reactive carbon atom at a specific site). This set of nine tools will be synthesized from a set of reactions that are made by a feedstock of atoms. Ralph and his colleages believe that computer models of these tools will work in real life. He gave some specific examples of his tools and the placement of carbons in molecular structures, as well as the energy that some reactions possess.

Regarding the development of nanotechnology, Ralph emphasized the need for writing proposals, ways to make the proposals work, money, further analysis of all reactions, development of directly accessible experimental pathways, and computer time, as well as duplicating results.

See: www.molecularassembler.com/Nanofactory/

What is the impact of nanotechnology?
Ralph foreseees more powerful computers, ones that will fit in the volume of a sugar cube and that are as powerful as all of the computer power in the world today. "This power will be so vast that we will be able to run Windows 2020!” he proclaims. He also thinks we will be able to make robotic arms on the scale of a few nanometers.

This kind of capability will certainly lead to a revolution in medicine. Today, loss of cell function results in cellular deterioration. Once a cell can no longer function, medicine is helpless to treat the problem and the cell dies. Cryonics is like clinical trials in that we will have to see if the technology will work around 2100. Dr. Merkle thinks the only logical choice is to sign up for cryonics and see if it works!

Dr. Merkle expressed the view that cryonics requires the development of nanomedicine based on mature nanotech. This is a long-term goal, and so far there are not a lot of groups that are working on this. Funding of long-term system design is minimal to non-existent. If we don’t start stepping up to the plate, development will be delayed. Therefore, the cryonics community needs to start leading this endeavor.

Commentary:
As this was the second time I have listened to Ralph, I was quite excited to hear his comparatively animated and interesting speech. His high-level concepts are explained in a relatively easy manner, and even though they reach a level of complexity of which I have very little background, I did not feel that the terminology was beyond my understanding. The chemistry presented in the talk was also easy to understand while using terminology such a “slurp of the hydrogen!” Ralph always makes me very excited about the field of nanotechnology, especially in relation to myself and the things that I will be able to see in the future.

*

Mike West, PhD ( by John Schloendorn)
Immortal Cells: The Prospect of Regenerative Medicine

Mike West, PhD, is the President and Chief Scientific Officer of Advanced Cell Technology, a firm leading the field in regenerative medicine using stem cells.

The key observation underlying Mike's work was that while individuals age and perish, the species as a whole can perpetually renew itself. In particular, although we are conceived by parents who are aged to varying degrees, each new generation is clearly, completely rejuvenated. Over the years, this led academic researchers to develop a dichotomy between the immortal germ-line and the mortal body cells of an individual, the “soma.” In particular, in the footsteps of August Weissmann and much later Tom Kirkwood, our mortal bodies came to be perceived as a disposable tool used by the immortal germ-line to maintain itself.

In a nutshell, Advanced Cell Technology seeks to tap the potential for immortality and transfer it into the cells of existing people. Dr. West's company is commercializing a key process to accomplish just this, namely therapeutic cloning. With therapeutic cloning, one can transfer the youthful characteristics of germ-cells into aged body cells.

For example, one of the mechanisms by which body cells senesce is through the gradual shortening of telomeres, the protective caps on the ends of the chromosomes containing the genes in our cells. Intriguingly, this shortening does not occur in germ cells, and telomere length of aged body cells can be restored by therapeutic cloning. Amazingly, therapeutic cloning also allows the conversion of any one type of aged cell into virtually any type of rejuvenated human cell, a quality termed "pluripotency." These resultant cells will be genetically identical to the donor’s aged cells. In theory, this would allow a transplant recipient to side-step any complications with transplant rejection. Indeed, Advanced Cell Technology was recently able to show that they can actually get all these marvelous processes to work in cows.

It is now clear that the cellular rejuvenation achieved by cloning is not only partial, but complete, because one can derive youthful individual organisms from aged, cloned cells, in a process called reproductive cloning. Although the possibility of reproductive cloning suggests that complete rejuvenation is achieved by the cloning process, Advanced Cell Technology has no interest in getting human reproductive cloning to work.

*

Aubrey de Grey, PhD (by Simone Syed)
Is it Politically Safe for a Biologist to Support Cryonics Publicly?

Dr. de Grey is Chairman and Chief Science Officer at the Methuselah Foundation.

Cryonics still has an image problem and scientific colleagues may be embarrassed, while the publications and lectures of a biologist supportive of cryonics may dry up completely! Certainly, Aubrey has encountered some challenging situations as a result of his public support of cryonics.

He spoke at length about the nature of peer-reviewed journals and the autonomy and, conversely, lack of autonomy these journals may provide in a scientist's career. The point of being a scientist is to make a big difference, as the pay is usually low, and very few in the field actually gain recognition.

Legal death, while often described as a purely instantaneous event, is clearly not instantaneous. Aubrey suggests providing the public with a clear definition of legal death, as "death" is purely defined according to the convenience of the doctors at the time. The definiton of death needs to remain under review, but it is doubtful that we will have a precise assay. Aubrey also states that "information theoretic death” may actually substantially preceed physical death, such as with dementia. This is, obviously, not good for the cryopreservation of these people, as their minds are corrupted already before they are declared deceased. Aubrey also points out that children who are "dead" after falling into frozen lakes have been resuscitated, so lack of electrical activity in the brain does not always mean certain death.

Ethical leadership cannot exist without facts, so Aubrey advocates coming up with better legal terminology to explain cryopreservation and those that are preserved. Aubrey makes the point that perhaps using the word "freezing" in relation to cryonics is fine because it is a concept that lay people can understand, and also, when we think about freezing, a steak for example, and thawing it out, it is just as delicious as it was before it ever was frozen. Thus, the word lends a hand to making people feel comfortable with the concept of vitrification in relation to humans.

Aubrey prefers not to refer to cryopreserved people as dead, or having experienced death, because it confuses the proper definition of death. Scientists have a moral duty to demystify scientific principles and make them more accessible for the general public to understand. By demystifying the concepts of death, regeneration, cryonics, and nanotechnology, they will get into the public consciousness and further demystify the concepts.

Finally, Aubrey ponders the impact on the scientific community of people who are largely invulnerable to scrutiny, due to not relying on grants and other public-perception means of support. Aubrey was able to come into his field in his spare time and has never been an experimental scientist. Therefore, he was able to be up-front about his intentions and his relationship to cryonics, which is very lucky.

It is time for scientists to start working together instead of against each other for progress. The arguments that radical scientists are putting forward are more often than not more sound than the arguments posed by non-radical thinkers. It may one day be more expedient to support cryonics outright and the tipping point for this may have already arrived. “My loyalties lie with the public and the scientists, not with politics.” The public must change their attitudes before tax dollars will be a reliable means of funding for the field of cryonics.

Commentary:
Aubrey’s discussion is summed up with emphasis that scientists have a duty to be the ambassadors of introducing new concepts into the mainstream. Apparently, this is the first time he has made this lecture, and people seemed relatively open to his ideas.

7th Alcor Conference, Saturday Morning Sessions

Special Guest Writers: John Schloendorn & Simone Syed

The 7th Alcor conference was held from Friday, October 5th to Sunday, October 7th in the Hilton Scottsdale Resort. The venue featured a level of luxury greater than a dewar, to say the least!

Friday evening began with a reception on the Hilton patio with light drinks and food. Also on Friday, Alcor public policy consultant Barry Aarons gave an introductory speech summarizing the recent progress of Alcor's status as a research entitity in Arizona. Indeed, within only four years, Alcor has progressed from being existentially threatened by the state government, to being perceived as an accepted research and technology institute furthering the public good. We are all grateful to Barry and the Alcor leadership for their excellent public relations work that made this possible. The next step should be to strengthen Alcor's relations with other leading biotechnology institutions in Arizona and to begin collaborations with efforts like the Biodesign Institute in Tempe, or the Bio5 in Tucson. In the long term, this should establish Alcor as an indispensible part of Arizona's sprawling academic and industrial biotechnology network.

Saturday morning's sessions featured talks from key individuals working to create and improve existing human cryopreservation technologies and processes. One of the first speakers, Brian Wowk, PhD, Senior Physicist at 21st Century Medicine, took us through the technical challenges and successes in cryopreservation research. Next, Alcor Executive Director Stephen Van Sickle gave us an overview of the research and process developments at the Alcor facility. Finally, Tanya Jones provided an in-depth look at current and future improvements in Alcor procedures and equipment.

Brian Wowk, PhD (by John Schloendorn)
Common Questions about Cryobiology and Cryonics

Brian Wowk, PhD, is the Senior Physicist of 21st Century Medicine, a company developing ice-free low temperature preservation solutions for a variety of applications, including cryonics. Brian addressed us with "Common Questions about Cryobiology and Cryonics." It turned out to be a dense talk, covering topics all across the many scientific disciplines required for successful cryopreservation.

The first topic dealt with how fozen cells get squeezed between ice-crystals. Interestingly, fish and other organisms from sub-zero environments can either avoid freezing (fish) or can tolerate the damage induced by freezing (frogs). Research at 21st Century Medicine focuses on the former strategy: Preventing freezing and ice-formation even at temperatures as low as -196C, the temperature of liquid nitrogen used to preserve cryonics patients. This process, called vitrification ("turning organs into a glass-like state") has led to an impressive list of isolated organs which can now be preserved ice-free at extremely low temperatures, without terminally damaging them. As one example, Brian took us through his now rather well-known results describing the cooling to -125C, thawing and successful transplantation of a rabbit kidney. This presentation featured a detailed photo story of the actual process and equipment used, which I had not seen before.

Next, Brian moved on to human cryopreservation. Of course, he was eager to point out that, unlike some organs, entire animals or humans cannot be cryopreserved at extreme temperatures and then repaired to a healthy state. This is only a theoretical possibility, upon which cryonicists rest their hopes. Thus, current cryopreservation protocols rely on the cryobiologist's best guess of how to minimize tissue damage. Brian took us through protocols currently used on Alcor's patients, involving perfusion with coolant/cryoprotectant and external ice packs. Ice-cooled patients are then rapidly shipped to Alcor for deep cooling and long-term care at the specialized facility. Up to 60% of a patient's body fluids can be replaced with cryoprotectant during the cryopreservation process.

According to Brian, "it is believed" that optimally executed, ice-free preservation (vitrification) of the brain can be achieved. However, in most human cases, the process is less than optimally executed because patients tend to be far away from the Alcor facility or their condition is not discovered rapidly enough. Thus, patients tend to sustain a much higher level of damage due to deprivation of oxygen delivery to tissues due to lack of circulation (ischemia) than the models Brian used in his research. Ideally, one would use more "realistic" processes on animal models to give the typical cryonics patient a better picture of what they can expect in the case of unforeseen death under a variety of circumstances. However, this is understandably not a priority of current research. In my opinion, the best an Alcor member can do is make efficient transport arrangements when diagnosed with terminal disease and move to Scottsdale if at all possible.

Finally, Brian alluded to potential techniques to repair any damage left by the cryopreservation protocols, such as damage caused by cryoprotectant toxicity, ischemia, residual ice formation, and freeze-fracturing. Other speakers went into more detail about these potential future technologies. In Brian's words, for now cryonics remains a technology to keep a patient's condition from deteriorating further.

In the end, I was left with this question: What has 21st Century Medicine actually been up to in the past couple of years? While Dr. Wowk's presentation provided excellent coverage of the background and basic science of cryopreservation (meeting its stated objective), it has been years since the rabbit kidney results were achieved. I can't help wondering about the research results at 21st Century Medicine since that time.

*

Stephen Van Sickle (by Simone Syed)
Research Directions at Alcor

Stephen Van Sickle has been Alcor Executive Director since 2005 and an active member of Alcor since 1992. He currently oversees the day-to-day operations at Alcor and is heavily involved in the development and deployment of new cryopreservation methods and technologies.

Stephen explained that research specific to cryonics is limited today, so Alcor needs to perform its own research, which will also provide valuable training experience and attract and retain key personnel.

Some of the questions being looked at include: What is Alcor most interested in as a research topic? How much of the whole body is vitrifying? How do our anti-ischemia drugs relate to cryoprotection? At exactly what point does cryoprotection become irreversible? How do we improve Alcor as an organization? How do we perform meaningful experiments in cryonics? How do we improve on current processes?

Stephen went into considerable detail about the importance of choosing an appropriate model system and controlling experiments, emphasizing the need to narrow the focus and control experiments by using a control group and an experimental test group to see what a difference of one variable will make.

He also discussed the application of cold in medicine, for instance when people are cooled to hypothermic temperatures and rewarmed, as well as when organs are cooled and transplanted in thousands of ORs across the country. These practices are reversible, and the relevant organ preservation solution experiments helped pave the way for cryopreservation.

Regarding Alcor's cardiopulmonary bypass lab which is being developed to test various aspects of the cryopreservation process, the rat model system is small, simple, and inexpensive. It is possible to perform one or two experiments a week per personnel. There is a wealth of experience from different laboratories on how to work with rats, and the Alcor lab has been constructed and its experiments designed to meet the standard animal care and use requirements. The lab has a specially-built surgical table and equipment that is sized to be flexible for use with many different types of animals. The scale is very difficult to work with because human-size equipment cannot be used on an organism comparably much smaller.

Once the model is established, what will be done with it? Alcor plans to conduct cryoprotection experiments. Previous work with dogs demonstrated that when 100% cryoprotection is used, an animal is not recoverable. Therefore, Alcor plans to research the point at which an animal is no longer perfusable and recoverable, and then to seek ways to move beyond that point. Incremental progress is what is needed in this area.

Fracture-free maintenance is a form of long-term care of cryopreserved people that prevents tissue fracturing. It is still in the research phase. Alcor is concerned about the fracturing that occurs while cooling cryonics patients to the glass transition temperature. How can this be stopped? The proposed fracture-free unit still needs to be tested in order to see if it is a usable solution for human care. With humans, fractures start long before cryonics patients are at the temperature of long-term care, -196C. This is distressing and the point of intermediate temperature storage is to curtail facture events. Alcor has begun its research by looking for tissue stresses using cross-polarized lenses, which are non-invasive and non-destructive. However, it was discovered a few weeks before this presentation was given that the equipment procured for this research was inadequate, and Stephen remarked that Alcor will now have to begin "from scratch" in order to assess the fracturing situation.

Stephen stated Alcor's perspective that "slow and steady wins the race." Alcor may be the tortoise of cryonics, but it is striving to be around for a long time and to eventually offer facilities all over the country and world.

Commentary:
This was a very informative talk about the more technological aspects of cryopreservation and the direction that new research at Alcor is taking. The lecture was a little dense at times, but in the 35 minutes, conveyed a vast amount of information. It is good to know that research is in the hands of someone who is passionate about the development of cryonics specific areas! I am glad to know that Alcor takes governmental requirements on research so seriously and is usually going above and beyond requirements.

*

Tanya Jones (by John Schloendorn)
Improving Cryopreservation Technology at Alcor

Tanya offered us a true deluge of recent and near-future improvements made to Alcor’s processes. The first critical step is the stabilization of a deceased patient for transport to the Alcor facility. The key intervention is, of course, cooling to zero degrees, which substantially slows the chemical reactions damaging the body of a patient whose heart has stopped. Within limits, airway management and cardiopulmonary support (without resuscitation) can maintain the oxygen supply to the patient’s organs during transport. Medication against damage induced by oxygen deprivation and blot clotting is also administered.

Tanya introduced substantial advancements being made at Alcor to streamline these processes and make them available to more patients. First and foremost, the stabilization network is now comprised of 73 Alcor members who provide a key local resource to help stabilize patients worldwide. Improved training and equipment for the stabilization networks’ volunteers are key on Alcor’s near-term agenda.

Tanya went on to give us a close-up presentation of Alcor’s new and under-development perfusion system, which comes in both stationary and mobile versions. The main foci of this innovative new system used during the cryopreservation process are automation, reliability and data collection. She discussed a number of projects underway at Alcor in detail, many of which were illuminated further at the Sunday afternoon facility tours.